Inozyme Pharma (INZY) – Research Analysts’ Recent Ratings Changes

Inozyme Pharma (NASDAQ: INZY) has recently received a number of price target changes and ratings updates:

• 3/12/2025 – Inozyme Pharma had its price target lowered by analysts at Raymond James from $24.00 to $12.00. They now have an “outperform” rating on the stock.
• 3/11/2025 – Inozyme Pharma had its price target lowered by analysts at Piper Sandler from $30.00 to $23.00. They now have an “overweight” rating on the stock.
• 3/11/2025 – Inozyme Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 3/11/2025 – Inozyme Pharma had its price target lowered by analysts at Needham & Company LLC from $23.00 to $15.00. They now have a “buy” rating on the stock.
• 3/10/2025 – Inozyme Pharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $12.00.

Inozyme Pharma Stock Up 1.0 %

NASDAQ:INZY traded up $0.01 during trading hours on Monday, reaching $1.01. 290,307 shares of the company traded hands, compared to its average volume of 505,904. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $3.20. The stock has a market capitalization of $64.88 million, a P/E ratio of -0.65 and a beta of 1.32. Inozyme Pharma, Inc. has a 1 year low of $0.98 and a 1 year high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in INZY. Harvest Investment Services LLC purchased a new position in Inozyme Pharma during the fourth quarter valued at $31,000. Graham Capital Management L.P. purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $38,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $49,000. Finally, ProShare Advisors LLC purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $49,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.